2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
3
Non-small Cell Lung Cancer Metastatic
2
Stomach Neoplasms
1
Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
1
Non-squamous Non-small Cell Lung Cancer
1
Lung Neoplasms
1
Breast Neoplasms
1
Breast Cancer Metastatic
1
Adenocarcinoma Gastric
1
Interventions
Pemetrexed
8
Carboplatin
6
Cisplatin
4
Bevacizumab
4
pembrolizumab
3
anlotinib
3
Platinum
2
Paclitaxel
2
tusamitamab ravtansine
1
ixabepilone
1
icotinib
1
endostar protein
1
camrelizumab
1
Gefitinib
1
Erlotinib Hydrochloride
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-squamous Non-small Cell Lung Cancer
×
tusamitamab ravtansine
×
Clear all
NCT05245071
2025-08-29
CARMEN-LC06
Sanofi
Phase 2
Terminated
22 enrolled
11 charts